Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06136364
Other study ID # senlangbio
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date August 15, 2023
Est. completion date August 14, 2038

Study information

Verified date November 2023
Source Hebei Senlang Biotechnology Inc., Ltd.
Contact Weili Zhao, Dr
Phone 0311-82970973
Email zwl_trial@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.


Description:

Main research purposes: To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL. Secondary research purposes: To preliminarily evaluate the efficacy, pharmacokinetics and pharmacodynamics of SENL101 in the treatment of patients with relapsed or refractory T-LBL/ALL. Exploratory research purpose: 1. To explore the immunogenicity of SENL101; 2. T cell NK cell recovery time after treatment;


Recruitment information / eligibility

Status Recruiting
Enrollment 9
Est. completion date August 14, 2038
Est. primary completion date August 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: According to the WHO hematopoietic and lymphoid tissue tumors classification, Subjects with refractory/relapsing T-LBL/ALL has been adequately treated and there is a lack of effective treatment, met one of the following criteria: 1. relapse: Primordial cells (>5%)in peripheral blood or bone marrow appeared again after complete remission with standard treatment or Extramedullary disease appears,include: 1. Early recurrence within 12 months, 2. Late recurrence at 12 months or above and with no remission after a course of standard induction chemotherapy, 3. Recurrence after autologous or allogeneic hematopoietic stem cell transplantation ; 2. Refractory: patients who have received at least two courses standard induction regimen and failed to achieve a complete response or complete remission was not achieved after first-line or above salvage treatment; 3. The tumor cells detected by bone marrow flow cytometry were CD7+ and/or extramedullary lesions were diagnosed as CD7+ by pathological immunohistochemistry at the time of enrollment and screening; 4. If tumor cells were detected in peripheral blood during enrollment and screening, it was required to meet the requirement that the surface immunophenotype of tumor cells was CD4 and CD8 double negative by flow cytometry. 5. Life expectancy greater than 12 weeks; 6. ECOG 0-2; 7. Age 18-75 (upper and lower limits included); 8. HGB at least 70g/L,PLT 50x109/L, can be transfused; 9. Liver and kidney functions The cardiopulmonary functions meet the following requirements: 1. Oxygen saturation under air = 92%; 2. LVEF=50%; 3. Total bilirubin <3×ULN; 4. ALT/AST<3×ULN; 5. Creatinine <1.5×ULN or creatinine clearance rate(Cockroft-Gault)>50ml/min; 10. Informed consent explained to, understood by and signed by patient/ guardian. Exclusion Criteria: Those who meet any of the following criteria are not eligible to join the group: 1. New York Heart Association (NYHA) classification = grade III heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris or other clinically prominent heart disease within one year before signing the informed consent form, Or QTc interval >480ms at screening (QTc interval calculated by Fridericia formula); 2. If the patient has a history of hematopoietic stem cell transplantation, 6 months after the patient received allogeneic hematopoietic stem cell transplantation; 3. Those with active GvHD or those who require immunosuppressive therapy; 4. Malignancy other than T-cell acute lymphoblastic leukemia/lymphoma within 5 years prior to screening, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer after radical surgery, radical surgery ductal carcinoma in situ; 5. History of non-neoplastic central nervous system disease (Seizures, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, neuropathy) 6. Active or uncontrollable infection requiring systemic treatment within 7 days prior to screening (except for mild urogenital infections and upper respiratory tract infections); 7. History of autoimmune disease (eg, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease) requiring systemic immunosuppressive/systemic disease modulating medication within the past 2 years; 8. When screening, if the hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HbcAb) is positive, and the peripheral blood hepatitis B virus (HBV) DNA is higher than the detection limit, it needs to be excluded; if the hepatitis C virus (HCV) antibody is positive, the peripheral blood HCV Those with positive RNA need to be excluded; those with positive human immunodeficiency virus (HIV) antibody; those with positive cytomegalovirus (CMV) DNA test; those with positive test for Treponema pallidum specific antibody (TPPA) need to be excluded; 9. Participate in other clinical trials within 4 weeks before the informed consent is signed, or the date of the informed consent is signed and the last medication of the drug is still within 5 half-lives of the drug (whichever is longer); 10. History of severe allergy to biological products; 11. Unstable systemic disease as judged by the investigator: including but not limited to severe liver, kidney or metabolic disease requiring drug therapy; 12. Pregnant or breastfeeding women, and female subjects planning pregnancy within 2 years of cell infusion or male subjects whose partner is planning pregnancy within 2 years of cell infusion; 13. Subjects who have received CAR-T therapy or other gene-modified cell therapy prior to screening; 14. Circumstances that the investigator believes may increase the risk to the subject or interfere with the results of the trial.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
CAR-T
CAR-T immunotherapy targeting CD7+

Locations

Country Name City State
China Shanghai Ruijin Hospital Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Hebei Senlang Biotechnology Inc., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety: Incidence and severity of adverse events Incidence and severity of adverse events 28 days after infusion
See also
  Status Clinical Trial Phase
Withdrawn NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1
Recruiting NCT04620655 - RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL N/A
Not yet recruiting NCT06434467 - The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma Phase 3
Recruiting NCT04582487 - Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL N/A
Suspended NCT04828174 - Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies Phase 1
Not yet recruiting NCT05068401 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1
Recruiting NCT03558412 - A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma Phase 4
Recruiting NCT05576532 - Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia Phase 2
Withdrawn NCT04860817 - A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL Early Phase 1
Recruiting NCT04004637 - CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia Phase 1
Recruiting NCT06376721 - Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma Phase 1/Phase 2